ASCO, ACCC publish recommendations on improving clinical trial diversity

Rybrevant leads to anti-tumor activity and durable responses in CRC, phase I/II follow-up results show

Longer follow-up results from the investigational phase Ib/II OrigAMI-1 study evaluating amivantamab-vmjw, a bispecific antibody targeting epidermal growth factor receptor and MET, in combination with FOLFOX or FOLFIRI chemotherapy in patients with RAS/BRAF wild-type metastatic colorectal cancer were presented during a poster session at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium.

January 16, 2026

Clinical Roundup

Bepirovirsen demonstrates positive results in chronic hepatitis B, phase III trials show

Positive results were announced from its two pivotal phase III trials, B-Well 1 and B-Well 2, evaluating bepirovirsen, an investigational antisense oligonucleotide for the treatment of chronic hepatitis B in over 1,800 patients from 29 countries.

January 16, 2026

Drugs & Targets

UAMS Winthrop P. Rockefeller Cancer Institute expands OnCore to strengthen clinical trials

The University of Arkansas for Medical Sciences Winthrop P. Rockefeller Cancer Institute has fully implemented the Advarra OnCore Clinical Trials Management System, an investment that strengthens oversight, efficiency, and growth of cancer clinical trials.

January 16, 2026

Clinical Roundup

Alliance prostate cancer trial seeks to reduce toxicity without sacrificing efficacy

The Alliance for Clinical Trials in Oncology initiated a randomized phase III clinical trial called RECIPROCAL to explore whether doctors can optimize the timing of targeted radiation therapy to minimize side effects while preserving efficacy in men with advanced prostate cancer.

January 09, 2026

Vol.52 No.1

Should I have a drink tonight?
In anticipation of the first holiday season since the surgeon general’s report on alcohol and cancer, we ask experts to weigh in

New Year’s Eve approaches, and with it, a chance to turn a new leaf with renewed energy, to reflect on—or perhaps, in the case of 2025, bemoan—the events of the year, and, most importantly, to celebrate.

MSK’s Deb Schrag elected president-elect of ASCO

Deborah Schrag, a gastrointestinal medical oncologist and George J. Bosl Chair of the Department of Medicine at Memorial Sloan Kettering Cancer Center, was elected 2027-28 president of the American Society of Clinical Oncology.

December 19, 2025

Vol.51 No.46

ASCO, ACCC publish recommendations on improving clinical trial diversity

YOU MAY BE INTERESTED IN

Rybrevant leads to anti-tumor activity and durable responses in CRC, phase I/II follow-up results show

Bepirovirsen demonstrates positive results in chronic hepatitis B, phase III trials show

UAMS Winthrop P. Rockefeller Cancer Institute expands OnCore to strengthen clinical trials

Alliance prostate cancer trial seeks to reduce toxicity without sacrificing efficacy

Should I have a drink tonight?
In anticipation of the first holiday season since the surgeon general’s report on alcohol and cancer, we ask experts to weigh in

MSK’s Deb Schrag elected president-elect of ASCO

Renew today!

Subscriber content

Never miss an issue!

Login

ASCO, ACCC publish recommendations on improving clinical trial diversity

YOU MAY BE INTERESTED IN

Rybrevant leads to anti-tumor activity and durable responses in CRC, phase I/II follow-up results show

Bepirovirsen demonstrates positive results in chronic hepatitis B, phase III trials show

UAMS Winthrop P. Rockefeller Cancer Institute expands OnCore to strengthen clinical trials

Alliance prostate cancer trial seeks to reduce toxicity without sacrificing efficacy

Should I have a drink tonight?In anticipation of the first holiday season since the surgeon general’s report on alcohol and cancer, we ask experts to weigh in

MSK’s Deb Schrag elected president-elect of ASCO

Never miss an issue!

Login

Should I have a drink tonight?
In anticipation of the first holiday season since the surgeon general’s report on alcohol and cancer, we ask experts to weigh in